COMPANY

Immunis

Immunis is a private biotechnology company targeting age-driven diseases and immune dysfunction. From company website Source · Oct 13, 2026

Keywords: private biotechnology Muscle Atrophy Sarcopenia Obesity and Obesity-related Medical Conditions Muscle Performance Sarcopenic Obesity IMM01-STEM

Profile checked Oct 10, 2026

$25.0MRaised (2 yrs)3Trials (company is sponsor)

Raises and deals from press releases

Raise Series A · $25M · announced Jan 11, 2025 Company release ↗
Source quote
- Jan 11, 2025 · Company release ↗
  “Immunis Closes $25 Million Series A-1”

Raises announced in these releases: $25M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Mar 5, 2026 Partnership Partnership / licensing announced Mar 5, 2026. Source: company's own press page. source ↗
Jan 11, 2025 Raise Private equity round — Series A-1: $25M (total, as published), announced Jan 11, 2025. Source: company's own press page. source ↗
Jan 11, 2025 Raise Series A · $25M source ↗
Dec 19, 2024 Trial start Phase 2: Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness source ↗
Sep 13, 2022 Trial start Phase 1/Phase 2: Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. source ↗

Funding

Raised: $25.0M. Last 2 years.

Jan 11, 2025 Private equity round — Series A-1: $25M (total, as published), announced Jan 11, 2025. Source: company's own press page. source ↗
Mar 5, 2026 Partnership / licensing announced Mar 5, 2026. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05211986	Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.	Phase 1/Phase 2	Completed	Sep 13, 2022	Jul 27, 2026 (actual)
NCT06784297	INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY	Not listed	Temporarily not available	Not listed	Not listed
NCT06600581	Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness	Phase 2	Active, not recruiting	Dec 19, 2024	Jul 15, 2026 (estimated)